Finance

Lists
RCEL:NASDAQ
AVITA Medical Inc
$13.05
0.00%
(0.00) 1D
Oct 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCEL...
Mkt. cap
403.60M
Avg. vol.
304.85K
Volume
605.00
52-wk high
$13.50
52-wk low
$3.22
EPS
-$1.44
Beta
1.99
Shares outstanding
30.93M
No. of employees
226
Mkt. cap
403.60M
Avg. vol.
304.85K
Volume
605.00
52-wk high
$13.50
52-wk low
$3.22
EPS
-$1.44
Beta
1.99
Shares outstanding
30.93M
No. of employees
226
News stories
From web sources and news partners
Profile
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts. Wikipedia
About AVITA Medical Inc
CEOJames Corbett
Employees226
Founded1999
HeadquartersValencia, California, United States
SectorBiotechnology
Websiteavitamedical.com
Analyst ratings
Based on 3 analysts giving stock ratings to RCEL in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RCEL in the last 3 months.
Highest
Current $13.05
$14.00 (+7.28%)
Average
$12.33 (-5.52%)
Lowest
$11.00 (-15.71%)
Analyst
Recommendation
Action
Price target
Projected
Date
Josh Jennings
TD Cowen
Buy
Maintained
$14.00
+7.3%
09/17/2026
Frank Takkinen
Lake Street
Buy
Reiterated
$12.00
-8%
08/28/2026
Ryan Zimmerman
BTIG
Buy
Maintained
$11.00
-15.7%
08/19/2026
Chad Messer
Lake Street
Buy
Reiterated
$6.00
-54%
07/16/2026
Carl Byrnes
Northland Securities
Buy
Maintained
$10.00
-23.4%
03/26/2026
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
17.06M
17.62M
19.25M
21.70M
Cost of goods sold
3.19M
3.30M
3.52M
3.94M
Cost of revenue
3.19M
3.30M
3.52M
3.94M
Research and development expenses
3.75M
5.69M
5.63M
5.08M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.28M
19.03M
18.90M
19.54M
Operating expense
23.03M
24.72M
24.53M
24.62M
Total operating expenses
26.22M
28.02M
28.05M
28.56M
Operating income
-9.15M
-10.41M
-8.80M
-6.86M
Other non operating income
49.00K
737.00K
-95.00K
-12.00K
EBT including unusual items
-13.17M
-11.64M
-10.62M
-7.63M
EBT excluding unusual items
-12.27M
-11.04M
-10.32M
-7.83M
Income tax expense
15.00K
-17.00K
-11.00K
33.00K
Effective tax rate
-0.11%
0.15%
0.10%
-0.43%
Other operating expenses
-
-
-
-
Net income
-13.19M
-11.62M
-10.61M
-7.66M
Net profit margin
-77.29%
-65.97%
-55.12%
-35.31%
Earnings per share
-
-
-
-
Interest and investment income
300.00K
200.00K
-
500.00K
Interest expense
-3.47M
-1.55M
-1.42M
-1.46M
Net interest expenses
-3.17M
-1.35M
-1.42M
-963.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.58M
-9.76M
-8.18M
-6.25M
Gain or loss from assets sale
252.00K
5.00K
55.00K
188.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps